ONKT 103
Alternative Names: ONKT-103Latest Information Update: 28 Jan 2025
Price :
$50 *
At a glance
- Originator ONK Therapeutics
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for preclinical development in Solid-tumours in Ireland (Parenteral)
- 09 Sep 2021 ONK Therapeutics has patent protection for CISH knockout in NK cells for use in cancer therapies in the US
- 09 Sep 2021 ONK Therapeutics has patents pending for CISH KO in NK cells in the US, the EU, China, Japan, Australia and New Zealand